17 slides from Shenzhen Mindray Bio-medical Electronics Co., Ltd. Class A's earnings presentation, October 2024
Slide 1: Mindray 2024Q3 Results Release and Earnings Call
Mindray 2024Q3 Results Release and Earnings Call Earnings Presentation 2024-10 1 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 2: Operating Highlights
Operating Highlights 2 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 3: Stable growth amidst multiple external challenges
Stable growth amidst multiple external challenges Q1-Q3 Net profit attributable to Q1-Q3 Revenue 29.48Billion RMB Q1-Q3 Net operating cash flow Shareholders 10.64Billion RMB YoY growth 8.0% 11.07Billion RMB YoY growth 8.2% YoY growth Q3 Revenue 8.95Billion RMB After excluding the impact of foreign e
Slide 4: Keep improving investor returns with more dividends
Keep improving investor returns with more dividends The Company proposes to distribute a cash dividend of 16.5 RMB for every 10 Dividend payout ratio 65.1% shares to all shareholders for the second 65.1% 60.7% interim dividends in 2024 56.8% Proposed a total of 6.92 billion RMB for twice interim 202
Slide 5: Increasing high-end penetration at international market and China market is under pressure in the short term
Increasing high-end penetration at international market and China market is under pressure in the short term International Market China Market Q1-Q3 Revenue 12.02 Billion RMB Q1-Q3 Revenue 17.47 Billion RMB YoY growth 18.3% YoY growth 1.9% Q3 Revenue YoY growth 18.6% Q3 Revenue YoY decline 9.7% Q3 R
Slide 6: In-vitro Diagnostics first become the largest business
In-vitro Diagnostics first become the largest business Patient Monitoring & Life In-vitro Diagnostics (IVD) Support (PMLS) Q1-Q3 Revenue 11.40 Billion RMB Q1-Q3 Revenue 10.89Billion RMB YoY decline 11.7% YoY growth 20.9% Accounting for Revenue 36.9% 38.7% Accounting for Revenue Minimally invasive su
Slide 7: Innovation and R&D
Innovation and R&D 7 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 8: Building an Ecosystem through Convergent Innovation
Building an Ecosystem through Convergent Innovation Q1-Q3 R&D spending Accounting for revenue 2.84 Billion RMB 9.6% 8 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 9: Blockbuster Products
Blockbuster Products In-vitro Diagnostics Segment 10 CLIA reagents such as Human Growth M980 Chemistry and Immunoassay Veterinary Immunoassay Analyzer Hormone and Insulin-like Growth Factor-1 Integrated Solution 9 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有 Note: This page lists only some of the new products in Q3
Slide 10: Blockbuster Products
Blockbuster Products Patient Monitoring and Life Support Segment UX7 4K+3D Endoscope System BeneHeart E/L/H Series BeneHeart R900/R700/R300 Semi-Automated AED Electrocardiograph 10 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有 Note: This page lists only some of the new products in Q3
Slide 11: Blockbuster Products
Blockbuster Products Medical Imaging System Segment TE Air e5M Wireless Handheld Ultrasound MX7 OBG Ultrasound Advanced version 11 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有 Note: This page lists only some of the new products in Q3
Slide 12: Sustainable Development
Sustainable Development 12 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 13: Information security and privacy protection
Information security and privacy protection • Mindray Medical Netherlands BV has earned the NEN 7510-1:2017 + A1:2020 certification for information security across the business • Mindray Italy has received a 2-star+ legality rating from the Italian Competition Authority, “Autorità Garante della Conc
Slide 14: Promoting public First Aid
Promoting public First Aid • Completed 190 first-aid training sessions in first three quarters, reaching over 7,000 participants • • Directly or indirectly mobilized 340,000 instances of participation in first-aid training • As of September 30, 2024, Mindray's AEDs have successfully treated 302 case
Slide 15: Smiles for All
Smiles for All ⚫ Donated medical equipment and established the first Operation Smile Medical Center in China ⚫ The medical center has cumulatively screened 267 patients and completed surgeries for 165 patients with cleft lip and palate 15 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 16: 2024Q3 Financial Statement
2024Q3 Financial Statement Billion RMB 2024 Q1-Q3 2023 Q1-Q3 YoY 2024Q3 2023Q3 YoY Revenue 29.49 27.30 +7.99% 8.95 8.83 +1.43% Gross margin 64.87% 64.16% +0.71pct 61.69% 61.14% +0.55pct Net profit attributable 10.64 9.83 8.16% 3.08 3.39 -9.31% to shareholders Net margin 36.08% 36.02% +0.06pct 34.36%
Slide 17: 17 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
17 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有